Home > Journals > Urology, Nephrology and Andrology International

Urology, Nephrology and Andrology International

Submit your article Read this Journals View all journals
Full Text (PDF)
Case Report

Skin and Nail Hyperpigmentation (Melanonychia) Due to Cyclophosphamide in Steroid Dependent Nephrotic Syndrome (SDNS): A Rare Association

Lakshminarayana G.R, Sahiba E Ummer

Author Information

Licence:

Attribution-Non-commercial 4.0 International (CC BY-NC 4.0)

This license enables reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator.

Urology, Nephrology and Andrology International 11(2):p 61-63, July - Dec 2025. | DOI: 10.21088/unai.2456-5016.10225.3

How Cite This Article:

Lakshminarayana GR, Ummer SE. Skin and Nail Hyperpigmentation (Melanonychia) Due to Cyclophosphamide in Steroid Dependent Nephrotic Syndrome (SDNS): A Rare Association. Uro Nephro Andro Int. 2025;10(2):61-3.

Timeline

Received : November 19, 2025         Accepted : December 20, 2025          Published : December 30, 2025

Abstract

Cyclophosphamide (CYC) is one of the most commonly used second-line drugs in the treatment of nephrotic syndrome, particularly in patients who are steroid-dependent or have frequent relapses. CYC may rarely cause skin or nail hyperpigmentation (melanonychia), in addition to its well-known adverse effects such as immunosuppression, cytopenias, or hemorrhagic cystitis. We present a patient with steroid-dependent nephrotic syndrome (SDNS) who developed blackish-brown discoloration of nails and periungual skin folds during therapy.

References

  • 1.   Kumar S., Dixit R., Karmakar S., Paul S. Unusual nail pigmentation following cyclophosphamide containing chemotherapy regimen. Indian J Pharmacol. 2010; 42(4): 243–4.
  • 2.   Marien L., Clarice J., Rachel G., Celso S., Ramos S.M. Chromonychia secondary to chemotherapy. Case Rep Dermatol. 2013; 5(2): 163–7.
  • 3.   Cristiana R., Beltrame G., Fenoglio R., Ferro M., Mesiano P., Quattrocchio G., Roccatello D. Blue 𿿿ngernails during treatment with cyclophosphamide for minimal change disease: a very rare side effect. Clin Med Rev Case Rep. 2017; 4: 162.
  • 4.   Mehta S., Makkar V., Soha P.M., Sethi S., Kaur S. Cyclophosphamide-induced melanonychia in a patient with steroid-dependent nephroticsyndrome: A rare presentation. Saudi J Kidney Dis Transpl. 2019; 30(4): 978–81.
  • 5.   Ranawaka R.R. Patterns of chromonychia during chemotherapy in patients with skin type V and outcome after one year of follow up. Clin Exp Dermatol. 2009; 34(8): e920–6.
  • 6.   Prajapati V.B., Madhyastha S., Acharya R., Gopalaswamy V., Doddamani A. Cyclophosphamide and doxorubicin-induced melanonychia: a case report. J Clin Diagn Res. 2017; 11(1): OD04–OD05.
  • 7.   Mary E.T., Murry D., Albert S.C. Ifosfamide induced hyperpigmentation. Cancer. 1993; 71(9): 2873–5.
  • 8.   Mendiratta V., Jain A. Nail dyschromias. Indian J Dermatol Venereol Leprol. 2011; 77(6): 652–8.5.

Data Sharing Statement

There are no additional data available. All raw data and code are available upon request.

Funding

This research received no funding.

Author Contributions

All authors contributed significantly to the work and approve its publication.

Ethics Declaration

This article does not involve any human or animal subjects, and therefore does not require ethics approval.

Acknowledgements

We would like to express our gratitude to the patients, their families, and all those who have contributed to this study.

Conflicts of Interest

No conflicts of interest in this work.

About this article

Cite this article

Lakshminarayana GR, Ummer SE. Skin and Nail Hyperpigmentation (Melanonychia) Due to Cyclophosphamide in Steroid Dependent Nephrotic Syndrome (SDNS): A Rare Association. Uro Nephro Andro Int. 2025;10(2):61-3.

Licence:

Attribution-Non-commercial 4.0 International (CC BY-NC 4.0)

This license enables reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator.

Received Accepted Published
November 19, 2025 December 20, 2025 December 30, 2025
DOI: 10.21088/unai.2456-5016.10225.3

Keywords

• Nephrotic syndromeCyclophosphamideMelanonychiaHyperpigmentationBlack chromonychia

Article Level Metrics

Last Updated

Saturday 05 September 2026, 22:39:08 (IST)

614

Accesses

17
149
00

Citations


NA
NA
NA

Download citation


Article Keywords

Keyword Highlighting

Highlight selected keywords in the article text.


Timeline

Received November 19, 2025
Accepted December 20, 2025
Published December 30, 2025

licence

Attribution-Non-commercial 4.0 International (CC BY-NC 4.0)

This license enables reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator.


Access this article

Reprint Order Form
Buy this Article
Institutional Subscriptions

Share